Research Guide · TR-3

What is TR-3?

A triple-peptide research composite of TB-500, BPC-157 and KPV combining cellular migration, angiogenesis and NF-κB anti-inflammatory pathways for multi-axis tissue repair research.

Updated September 2026 Research Use Only 11 min read

What is TR-3

A 30mg triple-peptide composite of TB-500 + BPC-157 + KPV addressing cellular recruitment, vascularisation, and inflammation modulation in one formulation.

Composite Identity

TR-3 (Tissue Repair 3-component) is a research composite of TB-500 + BPC-157 + KPV at 30mg total. Each component >99% HPLC verified.

Three-Axis Mechanism

TB-500 mobilises and recruits progenitor cells via G-actin sequestration; BPC-157 establishes local angiogenic priming via VEGF; KPV suppresses NF-κB inflammatory cascade via PepT1-mediated intracellular delivery. Three complementary axes of tissue repair.

Research Use Only

Strictly for in-vitro laboratory research and animal model studies. Not approved for human consumption or therapeutic application.

Component Mechanisms

Three peptides, three pathways.

TB-500 — Cellular Migration via G-actin Sequestration

17-amino acid Thymosin Beta-4 fragment; sequesters G-actin monomers regulating cytoskeletal dynamics that enable cellular migration to injury sites. Modulates inflammatory cytokine balance and recruits endothelial progenitor cells (Crockford et al., 2010; Goldstein et al., 2012).

BPC-157 — Angiogenesis & Cytoprotection

15-amino acid pentadecapeptide derived from human gastric juice; promotes angiogenesis via VEGF upregulation and nitric oxide synthesis; accelerates tendon, ligament, and gut barrier repair. Established neuroprotective effects in dopaminergic models (Sikiric et al., 2012; Sikiric et al., 2014).

KPV — NF-κB Inhibition via PepT1 Delivery

Tripeptide Lys-Pro-Val (alpha-MSH 11–13 fragment); enters cells via PepT1 (SLC15A1) transporter, particularly upregulated in inflamed colonic epithelium. Once intracellular, blocks NF-κB phosphorylation, suppressing TNF-α, IL-1β, IL-6, IL-8 (Brzoska et al., 2008; Catania et al., 2010).

Combined Pathway Coordination

In tissue repair models, the three axes coordinate: TB-500 recruits cells, BPC-157 vascularises the local microenvironment, KPV dampens inflammatory tone that would otherwise impair healing. The triple combination addresses recruitment + vascularisation + inflammation control simultaneously — a research model for multi-target repair pharmacology.

TR-3 vs Related Composites

How TR-3 compares to TR-2, GLOW70, KLOW80, and single-peptide protocols.

Composite

Components

Distinguishing Feature

TR-3

TB-500 + BPC-157 + KPV (30mg)

Adds KPV anti-inflammatory NF-κB inhibition; no copper signalling

TR-2

BPC-157 + TB-500

Lacks KPV; pure tissue-repair without inflammation modulation

GLOW70

GHK-Cu + BPC-157 + TB-500 (70mg)

Substitutes GHK-Cu (collagen/copper) for KPV; dermal regeneration focus

KLOW80

GHK-Cu 50mg + TB-500 + BPC-157 + KPV (10mg ea)

Includes both GHK-Cu and KPV; broadest 4-component coverage

Single-peptide

One peptide alone

Pathway isolation; no multi-target synergy

Research Context: TR-3 is positioned for research models where inflammation control is critical alongside tissue repair — IBD models, complex wound healing with infection risk, post-surgical inflammation, or dermatological inflammation. Researchers prioritising dermal regeneration may prefer GLOW70 (substitutes GHK-Cu); those wanting both copper signalling and anti-inflammatory may prefer KLOW80.

Key Research Applications

Primary research domains for TR-3.

GI Inflammation & IBD Models

KPV’s PepT1-mediated targeting of inflamed colon combined with BPC-157’s gut healing and TB-500’s cellular recruitment makes TR-3 well-suited for inflammatory bowel disease research models (DSS, TNBS-induced colitis).

Complex Wound Healing with Infection Risk

KPV’s antimicrobial activity against Gram-positive bacteria combined with TB-500/BPC-157 tissue repair pathways addresses chronic infected wounds where inflammation, bacterial load, and impaired repair coexist.

Post-surgical Inflammation Models

Surgical wound healing involves competing inflammatory and repair signals. TR-3 enables research into how anti-inflammatory KPV combined with pro-repair TB-500/BPC-157 might shift the balance toward earlier repair-phase transitions.

Dermal Regeneration with Inflammation Control

Atopic and inflammatory skin conditions involve chronic NF-κB activation that impairs barrier recovery. TR-3 provides research models where inflammation suppression accompanies tissue regeneration without requiring topical corticosteroids.

Tendon/Ligament Repair with Inflammatory Burden

Chronic tendinopathy involves degradation, failed repair, and persistent inflammation. TR-3’s three-pathway approach is studied in tendinopathy models where combined cellular migration, vascularisation, and inflammation modulation may yield better outcomes than single-axis interventions.

Quick Reference Specifications

Composite parameters.

P · 01

Designation

TR-3 (Tissue Repair 3-component composite)

P · 02

Components

TB-500 + BPC-157 + KPV

P · 03

Total Mass

30mg per vial (lyophilised)

P · 04

Component MWs

TB-500 ~889 Da; BPC-157 ~1,419 Da; KPV ~342 Da

P · 05

CAS Numbers

BPC-157: 137525-51-0; KPV: 67727-97-3; TB-500 (Tβ4 fragment): per supplier

P · 06

Purity

>99% HPLC per component

P · 07

Format

Lyophilised composite powder

P · 08

Mechanism Profile

Cellular migration + angiogenesis + NF-κB inhibition

P · 09

Storage (Lyophilised)

2–8°C; protect from light

P · 10

Storage (Reconstituted)

2–8°C with bacteriostatic water; stable 2–4 weeks

Reconstitution & Storage

Triple-peptide composite handling.

Reconstitution

Reconstitute with sterile bacteriostatic water (0.9% NaCl with 0.9% benzyl alcohol). Use sterile syringes; gentle dissolution with extended swirling (3–5 minutes) due to multi-component formulation. Avoid shaking.

Storage Timeline

Reconstituted TR-3 maintains bioactivity for 2–4 weeks at 2–8°C. All three components are stable in the same diluent. Avoid freeze-thaw cycles entirely.

Quality Control

Reconstituted solution should be clear and colourless to faintly yellow. Cloudiness, precipitates, or colour change indicates component degradation; discard.

Handling Best Practices

Maintain refrigeration; minimise air exposure; use fresh sterile needles per withdrawal; document reconstitution date; aliquot for extended programmes; discard solutions older than 4 weeks.

Component Evidence at a Glance

What the published literature supports for each ingredient.

TB-500

Cell migration & wound closure

Full-length Tβ4 accelerated re-epithelialisation in rat wounds; the LKKTETQ actin-binding motif used in TB-500 reproduced key pro-angiogenic effects in vitro. No human data for the fragment.^4–6

BPC-157

Angiogenesis & tendon repair

Rodent tendon, muscle and ischaemia models, including FAK–paxillin and VEGFR2–Akt–eNOS signalling. Human data: a two-participant IV safety pilot (2025).^1–3

KPV

NF-κB anti-inflammatory

PepT1-mediated uptake reduced colitis in DSS and TNBS mouse models, including with oral nanoparticle formulations. No human studies.^7–8

Regulatory & Research Status

Component status in 2026.

APR 26

FDA Category 2 removal

BPC-157, TB-500, KPV were among twelve peptides removed from the US FDA’s Category 2 compounding list. This is not an approval.

JUL 26

Advisory committee votes

The FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend BPC-157, TB-500 and KPV individually for the 503A bulks list. The votes are non-binding and do not cover combination products.

SPORT

WADA 2026

BPC-157 (S0) and TB-500 (S2) are prohibited at all times.

Evidence Quality & Limitations

No peer-reviewed study has tested TR-3 as a combination. The rationale rests on each component’s individual evidence and complementary mechanisms, so “synergy” is a hypothesis to test rather than an established finding. Component ratios reflect the product formulation rather than published dose-response work, and the stability and compatibility of the peptides stored together in one solution have not been characterised in the literature. Nearly all component data are preclinical.

References

Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–80. PubMed
Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323–33. PubMed
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–4. PubMed
Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364–8. PubMed
Philp D, et al. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17:2103–5. PubMed
Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A. 2012;1265:57–69. PubMed
Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166–78. PubMed
Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25:1628–40. PubMed

⚠ Research Use Only. The compounds discussed in this guide are intended strictly for in-vitro laboratory research. Not for human consumption, therapeutic use, or veterinary application. Researchers must comply with all applicable local regulations.